EDTA Chelation / Heavy Metal Detox / Plaque Chelation
IV infusion of EDTA (ethylenediaminetetraacetic acid) — a synthetic amino acid that binds to heavy metals and certain minerals in the bloodstream, forming stable complexes that are excreted through the urine — used clinically for heavy metal poisoning and explored off-label for cardiovascular disease.
How it works
EDTA is a non-selective chelating agent with high affinity for divalent metal cations (lead, mercury, cadmium, arsenic, and also calcium). Approved mechanism: binds circulating toxic metals forming water-soluble complexes cleared by kidneys. Cardiovascular use (controversial): TACT trial (NIH-funded) showed modest benefit in patients post-MI with diabetes — proposed mechanism involves chelating calcium from arterial plaques and reducing oxidative stress from metal-catalysed reactions.
Reported benefits
- Heavy metal toxicity treatment (lead, mercury, arsenic)
- Cardiovascular health support (adjunctive; some clinical evidence in diabetic patients)
- Reduction of oxidative stress from metal-catalysed free radicals
- General detoxification support
- Used adjunctively in autism spectrum conditions (highly controversial — consult specialist)
Regulatory status
Approved for: Heavy metal poisoning (approved), Cardiovascular support (off-label in some countries)
EDTA approved as a medicine for heavy metal toxicity across EU. Cardiovascular chelation more widely practiced (off-label) in Germany, Austria, and some Eastern European countries. EMA has not specifically approved CV chelation.
Approved for: Heavy metal poisoning treatment (licensed use), Cardiovascular and wellness use (off-label)
EDTA licensed as medicine for metal poisoning. Off-label cardiovascular use exists at private integrative medicine clinics. NHS uses chelation for heavy metal poisoning. Must be prescribed and administered by registered physicians.
Approved for: Lead poisoning treatment (approved), Mercury, arsenic, gold poisoning (approved), Cardiovascular disease (off-label, TACT trial showed modest benefit in diabetics post-MI)
EDTA IV is FDA-approved since 1953 for lead and heavy metal poisoning — the original approved indication. Cardiovascular use is off-label. The TACT (Trial to Assess Chelation Therapy) NIH-funded study showed a modest benefit in diabetics post-MI, leading to TACT2 trial. FDA requires careful monitoring of calcium and kidney function.
Practical details
Frequency: Series of 20–30 sessions, twice weekly; maintenance monthly
Results last: 1.5–3 hour infusion sessions; results accumulate over the course
Contraindications:
- Kidney disease or impaired renal function (EDTA is cleared renally)
- Hypocalcaemia (EDTA binds calcium and can cause dangerous drops)
- Pregnancy
- Heart disease requiring careful management (must be medically supervised)
- Allergy to EDTA or corn products
Always consult a licensed medical professional before undergoing any treatment. This information is educational only and does not constitute medical advice.